Home Cart Sign in  
Chemical Structure| 2097002-61-2 Chemical Structure| 2097002-61-2

Structure of Selitrectinib
CAS No.: 2097002-61-2

Chemical Structure| 2097002-61-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LOXO-195 is a TRK kinase inhibitor (TKI) with IC50 values of 0.6 nM and <2.5 nM for TRKA and TRKC, respectively.

Synonyms: LOXO-195; BAY 2731954

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Hiroki Kobayashi ; Tadashi Iida ; Yosuke Ochiai ; Ermanno Malagola ; Xiaofei Zhi ; Ruth A. White , et al.

Abstract: Cancer-associated fibroblasts (CAFs) and nerves, components of the tumor microenvironment, have eachbeen shown to directly promote gastrointestinal cancers. However, it remains unknown whether these cells interact with each other to regulate cancer progression. We found that in colorectal cancer (CRC) norepinephrine induces ADRB2-dependent nerve growth factor (NGF) secretion from CAFs, which in turn increases intra-tumor sympathetic innervation and norepinephrine accumulation. Adrenergic stimulation accelerates CRC growth through ADRA2A/Gi-mediated activation of Yes-Associated Protein (YAP). NGFfrom CAFs directly enhances CRC cell growth via the PI3K/AKT pathway. Treatment with a tropomyosinreceptor kinase (Trk) inhibitor decreased YAP and AKT activation and CRC progression in mice. In human CRC, high NGF expression is associated with the mesenchymal-like tumor subtype and poor patient survival. These findings suggest a central role for reciprocal CAF-nerve crosstalk in promoting CRC progression. Blocking this feedforward loop with a Trk inhibitor may represent a potential therapeutic approach for CRC.

Keywords: colorectal cancer ; tumor microenvironment ; fibroblasts ; nerve growth factor ; sympathetic nerves

Purchased from AmBeed:

Alternative Products

Product Details of Selitrectinib

CAS No. :2097002-61-2
Formula : C20H21FN6O
M.W : 380.42
SMILES Code : O=C1C2=C(N3N=C2)N=C(C=C3)N4[C@@](CCC4)([H])C5=CC(F)=CN=C5CC[C@@H](C)N1
Synonyms :
LOXO-195; BAY 2731954
MDL No. :MFCD31620755
InChI Key :OEBIHOVSAMBXIB-SJKOYZFVSA-N
Pubchem ID :129103609

Safety of Selitrectinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Selitrectinib

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
KM12 colon cancer cells 0.001、0.01、0.1、1 、10 μM Drugs and cell viability assay PMC11194613
IRC and KM12 cells 1-5000 nM 72 hours To assess the effect of Selpercatinib on the growth inhibition and TRK-mediated signaling in NTRK fusion-positive tumor cells. Results showed that Selpercatinib significantly inhibited tumor cell growth and TRK signaling. PMC11300601
IRC and KM12 cells 1-5000 nM 72 hours To assess the effect of Selpercatinib on the growth inhibition and TRK-mediated signaling in NTRK fusion-positive tumor cells. Results showed that Selpercatinib significantly inhibited tumor cell growth and TRK signaling. PMC11300601
Ba/F3 (LMNA-NTRK1, TRKA G595R) 100 nM 30 min To test the inhibitory effect of Selitrectinib on TRKA G595R mutant cells, results showed inhibition on this mutation. PMC11300601
Kor1 (TPM3-NTRK1) 100 nM 30 min To test the inhibitory effect of Selitrectinib on NTRK fusion-positive cells, results showed inhibition on Kor1 cells. PMC11300601
IRC (LMNA-NTRK1) 100 nM 30 min To test the inhibitory effect of Selitrectinib on NTRK fusion-positive cells, results showed inhibition on IRC cells. PMC11300601
NIH3T3 cells 18.7–341 nmol/L 72 hours Evaluate the inhibitory effect of Selitrectinib on TRKA/B/C resistance mutations, showing moderate inhibitory activity against solvent-front (SFM) and xDFG mutations PMC9762329
Ba/F3 cells 1.8–3.9 nmol/L 72 hours Evaluate the inhibitory effect of Selitrectinib on wild-type TRKA/B/C fusion proteins, showing moderate inhibitory activity PMC9762329

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude female mice KM12 (TPM3-NTRK1) xenografts Oral 30 mg/kg BID Twice daily for 10 days To test the inhibitory effect of Selitrectinib in vivo on NTRK fusion-positive tumors, results showed inhibition on KM12 model. PMC11300601
Nude mice Patient-derived xenograft (PDX) model Oral 100 mg twice daily, escalated to 150 mg twice daily, and finally to 200 mg twice daily Twice daily for over 5 months To evaluate the efficacy of Selitrectinib in metastatic undifferentiated sarcoma harboring NTRK1 G595R solvent-front mutation. Results showed a partial response with reduced fluorodeoxyglucose uptake and slow disease progression, with increased plasma drug levels upon dose escalation. PMC7055910
Nude mice NIH3T3 LMNA–TRKAG595R xenograft model Oral 30 mg/kg Twice daily, continuous treatment Evaluate the inhibitory effect of Selitrectinib on TRKA G595R mutant tumors, showing 80% tumor growth inhibition PMC9762329

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.63mL

0.53mL

0.26mL

13.14mL

2.63mL

1.31mL

26.29mL

5.26mL

2.63mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories